Business Wire

Eucafluff Expands Businesses in Europe, Asia, and in the United States

11.4.2019 09:00:00 EEST | Business Wire | Press release

Share

Suzano (NYSE:SUZ), a merger between Suzano Papel e Celulose and Fibria, has increased Eucafluff sales in the European, Asian, and US markets. The product is the only eucalyptus-based fluff pulp sold in the world and is used in personal hygiene items such as diapers and sanitary napkins. Eucafluff is considered a reference of innovation and sustainability and, therefore, has been approved by major global manufacturers. In the last 6 months, companies such as Ontex and Vinda International, amongst other local players in Europe, the United States, Japan, and China have been buying from Suzano.

Currently, 86% of Eucafluff's sales are made overseas, in which 25% are sold in Europe. "The acceptance of our fluff pulp in mature markets and multinational companies has confirmed the good performance that eucalyptus fiber can also bring to the hygiene market. We are committed to improving the quality and performance of our client’s end products and this has reflected in the global partnerships we have achieved these past months, " says Alexandre Corrêa, Executive Manager of the Business Unit at Suzano.

Developed by Suzano and resulting from 11 years of research, Eucafluff is the first bleached kraft pulp of eucalyptus fluff type in the world, and is be applied in absorbent products as well as personal hygiene products, disposables like children and adults diapers, sanitary napkins for women, amongst other applications. The key benefits provided by this unique fiber are a higher liquid absorption and retention at product cores and greater comfort and discretion to the end user, such as in the case of application in incontinence pants. These benefits are due to the greater compressibility of the eucalyptus fiber, a feature that has also brought other associated benefits as reduction in packaging size, transportation, and storage costs.

Suzano has 95 years of history and 11 factories, and is present in the lives of more than 2 billion people through its products. The company is the world´s leader in the production of eucalyptus pulp, a raw material developed by the company in the 1960s, is also a world pioneer in the production of eucalyptus fluff and is one of the largest paper manufacturers in Latin America. Since its inception, it has invested in innovative and unique solutions, seeking the substitution of raw materials of fossil origin for other sources of renewable origin.

About Suzano

Suzano , the company resulting from the merger of Suzano Pulp & Paper and Fibria, is committed to being a global reference in the sustainable use of natural resources. The world's leading producer of eucalyptus pulp and one of Latin America’s largest paper producers, Suzano exports to more than 80 countries and, through its products, plays a part in the lives of over two billion people. With ten mills and the joint operation Veracel, Suzano has annual installed capacity of 11 million tons of market pulp and 1.4 million tons of paper. Suzano has approximately 37,000 direct and indirect employees and for over 90 years has invested in innovative solutions based on eucalyptus cultivation that enable it to substitute the use of fossil-based materials with renewable bio-based materials. The company adopts the highest standards of corporate governance on the exchanges where its stock is traded, namely the B3 in Brazil and the NYSE in the United States.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PLANIN – Suzano’s PR Agency
Angélica Consiglio, Beatriz Imenes and team – www.planin.com
E-mail: suzano@planin.com - Phone: +55 (11) 2138-8940

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye